Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Can AVIPTADIL help…???



The researchers, who report their findings today in Nature, analyzed human lung tissue to identify the new cells, which they call respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that RASCs have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of RASCs -- hinting that correcting this disruption could be a good way to treat COPD.

"COPD is a devastating and common disease, yet we really don't understand the cellular biology of why or how some patients develop it. Identifying new cell types, in particular new progenitor cells, that are injured in COPD could really accelerate the development of new treatments," said study first author Maria Basil, MD, PhD, an instructor of Pulmonary Medicine.

https://www.sciencedaily.com/releases/2022/04/220401122222.htm

The most abundant neuropeptide in the lung is the vasoactive intestinal peptide (VIP), which is a potent muscle relaxant and has therefore been suggested in the therapy of chronic inflammatory lung diseases, including COPD [15,16]. In experimental conditions, VIP has a positive inotropic and chronotropic effect.

https://www.karger.com/Article/Fulltext/439228

The global asthma and COPD drugs market size was US$ 34522.6 million in 2021. The global asthma and COPD drugs market size is forecast to reach US$ 53049.54 million by 2030, growing at a compound annual growth rate (CAGR) of 4.65% during the forecast period from 2022 to 2030.

https://www.marketwatch.com/press-release/asthma-and-copd-drugs-market-2022-industry-outlook-share-size-opportunities-and-forecast-to-2030-2022-03-25